Back to top

Image: Bigstock

The Zacks Analyst Blog Highlights: Mastercard, Pfizer, Nike, Lockheed Martin and Micron Tech

Read MoreHide Full Article

For Immediate Release

Chicago, IL – December 1, 2021 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Mastercard Inc. (MA - Free Report) , Pfizer Inc. (PFE - Free Report) , Nike, Inc. (NKE - Free Report) , Lockheed Martin Corporation (LMT - Free Report) and Micron Technology, Inc. (MU - Free Report) .

Here are highlights from Tuesday’s Analyst Blog:

Top Research Reports for Mastercard, Pfizer and Nike

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Mastercard, Pfizer, and Nike. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Shares of Mastercard have outperformed the Zacks Financial Transaction Services industry over the past year (-4.2% vs. -24%). The Zacks analyst believes that Mastercard's profit levels have been rising on the back of higher consumer spending, and is well-poised to gain from steady cash-generating abilities.

Strategic acquisitions, alliances and technology upgrades, along with product-diversification and geographic-expansion initiatives bode well for the long term. Mastercard uses acquisitions to supplement its organic efforts and diversify its revenues. A strong capital position enables MA to pursue acquisitions and deploy capital. High expenditures, higher rebates as well as incentives, however, are likely to weigh on Mastercard's margins.

(You can read the full research report on Mastercard here >>>)

Pfizer shares have gained +48% in the year-to-date period against the Zacks Large-Cap Pharmaceuticals industry’s gain of +16.7%. The Zacks analyst believes that Pfizer’s licensing deals and collaborative agreements are likely to drive growth in the near term.

The Consumer Healthcare JV with Glaxo and merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. Strong growth of key brands like Ibrance, Inlyta and Eliquis are also expected to drive sales. PFE’s COVID-19 vaccine has become a key contributor to the top line. Currency headwinds and pricing pressure, however, remains as the top-line headwinds.

(You can read the full research report on Pfizer here >>>)

Shares of Nike have gained +24.7% in the past six months against the Zacks Shoes and Retail Apparel industry’s gain of +22.7%. The Zacks analyst is impressed with Nike’s product innovation, brand strength and scale of operations.

Strong Nike Direct sales, led by the return of traffic to stores and digital momentum aided the fiscal first quarter results. In fiscal 2022, Nike expects consumer demand to remain robust, driven by its strong customer connections and brand momentum. NKE has, however, been battered by supply-chain woes and the closure of Vietnam and Indonesia factories, resulting in product shortages.

(You can read the full research report on NIKE here >>>)

Other noteworthy reports we are featuring today include Lockheed Martin and Micron Technology.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339                                                                        


Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release.